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In the Western Cape Province of South Africa, tuberculosis (TB) is a major health problem and 
in 2012 accounted for 7.40% of premature deaths. The Province has experienced an increase 
in TB incidence in the past 20 years. 
Objectives 
The aims of the study were to describe the distribution of tuberculosis and identify risk factors 
associated with TB treatment outcomes in public sector tuberculosis facilities in the Western 
Geographic Service Area of the Cape Town Metropole District. 
Methods 
A cross sectional study was conducted using data collected in electronic TB registers from June 
2011 to July 2012. Patients initiated on TB treatment aged 15 years and above with a known 
treatment outcome were included in the study.  
Results 
The study included 10 251 TB patients registered during the study period who had a final 
treatment outcome and 55.35% (5 674) were males. The mean age was 36.0 years and 72.20% 
(7398) were new cases. Most patients had pulmonary TB (83.21%). Almost half of the patients 
(49.62%) were co-infected with HIV. 
Of the 10 251 cases, 47.02% (4 820) completed treatment, 37.43% (3 837) were cured, 8.67% 
(889) defaulted, 5.18% (531) died and 1.70% (147) failed treatment. There was a significant 
association between treatment outcome and sex, disease classification, treatment regimen, HIV 
status and patient category. 
Conclusion 
A high proportion of incident TB cases had previously been treated for TB.  Overall treatment 
outcomes were poor. Unfavourable treatment outcomes were more common in men, those with 
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The World Health Organization (WHO) reported that the fight against tuberculosis (TB) has 
yielded some positive results in the reduction of cases and deaths.1 Although progress has been 
noted in the targets set in the Millennium Development Goals such as a 2% decline in TB 
incidence rate and 45% decline in the mortality rate since 1990, TB remains a major global 
health problem.1 It causes morbidity each year in millions of people and is the second leading 
cause of death from an infectious disease worldwide following Human Immunodeficiency 
Virus (HIV).  
 
Global burden of Tuberculosis 
 
According to the WHO Tuberculosis report 2013, in 2012 there were 8.6 million new cases of 
TB disease and 1.3 million TB deaths (including 320 000 deaths among HIV-positive persons). 
About 13% of the 8.6 million people with TB in 2012 were HIV positive and 75% of these 
cases were from Africa. Most TB cases including deaths occurred in men but the burden of 
disease among women was also high. There was an estimated 410 000 TB deaths among 
women in 2012 including 160 000 among HIV-positive women.1 WHO recommends the global 
TB strategy in the treatment and control of TB and 56 million people were successfully treated 
for countries that had adopted WHO global TB strategy between 1995 and 2012 saving about 
22 million lives.1 The target set by World Health Assembly in 1999 for treatment success is 
85% and the global cohort that was treated in 2011 (2.6 million) as new cases of sputum smear-
positive pulmonary TB attained 87% treatment success, meeting and exceeding the excepted 
treatment success rate however, the African region had 82% which is slightly below the set 
target.1  
 
TB control and Treatment 
 
WHO recommends following the DOTS programme in the control of TB. The programme 
consists of five elements; political commitment, case detection by sputum microscopy, 
standardized short-course chemotherapy, sustainable drug supply and standardization of 
recording and reporting. Most national TB programmes have adapted this programme in the 
fight against the spread of TB and strive to reach treatment completion rates of 85% and case 
detection rates of 70% which are required to have an impact on the TB epidemic.2 On the other 
9 
 
hand WHO developed TB Treatment guidelines and recommendations that TB control 
programmes in most countries have adopted. The aims of the tuberculosis treatment 
programme are; to cure patients of the infection and to restore their quality of life, to prevent 
death or prolonged ill health due to TB, to prevent the relapse of TB, to reduce transmission of 
TB to others as well as to prevent the development and transmission of drug resistance.2 
The strength of TB control remains in establishing and managing standardized treatment across 
the country for all TB cases – sputum smear-positive, smear-negative, and extra pulmonary. It 
is advised that in all cases, WHO guidelines on patient categorization and management are 
followed.2 South Africa is currently using the 2013 treatment guidelines. 
 
TB Treatment outcomes 
 
Monitoring treatment outcomes is one component that is essential for understanding the 
effectiveness of TB control programmes3 and lead to the identification of risk factors for 
unsuccessful treatment and specific high risk groups that need targeted efforts.4 The outcome 
categories follow the guidelines set by WHO and include the treatment outcomes; cured, 
treatment completed, treatment failure, died, defaulted or transferred out.2 These treatment 
outcomes are defined as follows;  
 Cured; a patient whose sputum or culture was positive at the beginning of the treatment 
but who has smear or culture that was negative in the last month of treatment and on at 
least one previous occasion. 
 Treatment complete; a patient who completed treatment but who does not have a 
negative sputum smear or culture in the last month of treatment and on at least one 
previous occasion. The sputum examination may not have been done or the results may 
not be available. 
 Treatment failure; a patient whose sputum smear or culture is positive at 5 months or 
later during treatment. Also included are patients with multidrug-resistant (MDR) strain 
at any point of time during the treatment, whether they are smear-negative or positive. 
 Died; a patient who dies for any reason during the course of treatment. 
 Default; a patient whose treatment was interrupted for 2 consecutive months or more. 
 Transfer out; a patient who has been transferred to another recording and reporting unit 
and whose treatment outcome is unknown. Therefore, the final TB treatment can be 
categorized into successful outcomes and unsuccessful outcomes.  
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 Treatment success; the sum of cured and completed treatment.  
 Treatment interruption: Those that interrupted treatment for two (2) consecutive days 
or more during intensive phase, two (2) weeks or more during continuation phase and 
those that interrupted treatment for two (2) months or more after the date of the last 
attendance from the last treatment (defaulters) were regarded as having interrupted 
treatment.2 
The final TB outcomes are categorized into successful outcomes or favourable outcomes and 
unsuccessful outcomes or unfavourable outcomes. A successful outcome includes TB patients 
who are cured or have completed TB treatment; while unsuccessful outcome consists of 
defaulted, died or failed treatment.  
One tool that allows the assessment of treatment outcome is the Electronic TB register 
(ETR.net). The register provides information on the socio-demographics of persons on TB 
treatment and their outcomes.  It provides easy and convenient collection, compilation, and 
analysis of TB data on a continuous basis.5 The advantages of the use of ETR.net include: 
 Data entry is at district level. 
 The reports are standardised allowing data to be compared at national level as well as 
at international level. 
 It allows for cohort analysis matching case finding, smear conversion, treatment 
outcomes reports, HIV testing and services for TB patients. 
 It has a patient listing which is a useful programme management tool to trace patient 
outcomes.  
 The ETR.net has data check. This data entry validation offers flexibility to enrich 
analysis as TB/HIV care evolves. 
 Reports and summaries are produced by any time period such as quarterly or yearly at 
all reporting levels. 
 The register has security access passwords for administrators and workgroups. 
The ETR.net has some pitfalls: 
 No changes are allowed such as adding and deleting of reporting units or change of 
district boundaries. 
 The ETR has a standard reporting generator that does not allow for easy interface with 




 The register is district based and therefore, cannot focus on individual clinics. Clinic 
based performance review can be important in isolating areas to improve the TB 
programme performance. 
 The system requires adequate human resource and if this is lacking, poor data quality 
and poor outcomes may be blamed on the system. 
 
Tuberculosis in South Africa 
 
South Africa has one of the worst tuberculosis epidemics in the world, with a high disease 
burden, incidence rates and HIV co-infection rates, and growing epidemics of multi-resistance 
and extensively drug resistance tuberculosis.6 In 2012, 24% of new and relapse TB cases 
globally were from African countries and one quarter of these cases were from one country - 
South Africa.1The WHO reported that in 2012 South Africa was among five countries with the 
highest number of incident cases. These countries included India (2.0 million–2.4 million), 
China (0.9 million–1.1 million), South Africa (0.4 million–0.6 million), Indonesia (0.4 million–
0.5 million) and Pakistan (0.3 million–0.5 million).1 The estimated incidence of tuberculosis 
in South Africa in 2012 was 1003 cases per 100 000 population,1 compared to 266 cases per 
100 000 population in 2003.7  Despite having the worst TB epidemic, South Africa has 
continued with efforts to prevent and control the spread of TB upholding the cornerstone of TB 
control of proper detection and treatment completion of new cases of TB disease under the 
DOTS programme.  In 1995 the country adopted the DOTS programme as the standard care 
for TB although it has been noted that the implementation has not been consistent.6  TB drug 
resistance surveillance has been enhanced and TB programmes and patients TB treatment 
outcomes are monitored through the TB register.6 In 2012 in South Africa 296 996 new cases 
of TB were notified.1 New cases are patients who have never previously had TB treatment or 
taken anti-TB drugs for less than 1 month.2 They may have positive or negative bacteriology 
with the disease at any anatomical site. Of the new cases 40% (119 898) were smear positive, 
21% (63 210) were smear negative and 24% (71 421) did not have a smear or the result was 
not known, while 14% (42 467) had extra pulmonary TB.1 There were 52 586 retreatment cases 
(18% of all cases) where patients had previously received treatment for 1 month or more. Of 
the retreatment cases 51% were relapse cases (patients who were declared cured or treatment 
completed but reported back to the health service and were found to have a positive sputum 
smear), 6% were treatment after failure (patients who still had a positive bacteriological test 
after the completion of treatment), 15% were treatment after default (patients who had stopped 
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receiving treatment for more than 2 months) while 28% had another reason for retreatment.1 
Treatment success rate varied for the different treatment categories for the 2011 cohort included 
in the 2012 report, new smear positive and/or culture positive had a 79% treatment success 
rate, while new smear negative/extra-pulmonary  had a 67% and  retreatment cases had a 66% 
treatment success rate.1 The achieved treatment success rates were below the WHO expected 
rate of 85%. 
  
Tuberculosis in the Western Cape Province 
 
In the Western Cape Province of South Africa, TB is a major health problem and in 2012 
together with HIV and interpersonal violence, accounted for the largest proportion of premature 
mortality (HIV/AIDS; 12.0%, interpersonal violence; 9.2% and tuberculosis; 7.4%).8 
Historically, the Western Cape Province has had the highest rates of tuberculosis in the 
country.9,10 It remains the province with the highest incidence of new TB cases and  showed an 
annual increase of 8-10% in registered TB cases during the period 1997 to 2005.11  
In the past 20 years the province has experienced an increased TB incidence rate particularly 
in the coloured population.10 This population accounted for 42.4% of the Cape Town 
population in 2011.12 Despite the increase in TB incidence there has however been a stable 
annual risk of infection in this high risk group.8 The average annual risk of infection calculated 
as an average prevalence of infection, approximates the incidence of infection and indicates 
the extent of transmission in a community. This could reflect the high prevalence observed in 
the coloured community.10 Claassens et al. attributed the increase in TB incidence to the 
inability of the health services to reduce new infections in the communities. Late presentation 
has also led to an increase in the infectious pool and this is aggravated by overcrowding and 
poor social conditions. There are also other risk factors for TB disease such as poor nutritional 
status, alcoholism and unemployment.13 Poor patient compliance and several health service 
impediments have resulted in a large number of patients not being retained on treatment until 
cure.10 The emergence of drug resistance TB also poses a threat to the control of the spread of 
TB. At the national level multi-drug resistant TB (MDR-TB) in 2013 comprised 1.8% of new 
cases and 6.9% of previously treated cases of TB in South Africa.1   
In Western Cape, the cure rate for new smear positive TB is 80.5%, although below the WHO 
target of 85%, the rate is the highest TB cure rate achieved in South Africa.14 
13 
 
Cape Town Metro District 
TB is a major contributor to the burden of disease in Cape Town with a 66% increase in the 
number of TB cases notified between 1997 and 2003.15 Despite the reported increase in TB 
incidence in Cape Town the TB Control Programme aims to identify 80% of people who have 
TB and to cure them at the first attempt.15  
 
TB caseload varies across the sub-districts of Cape Town and in 2002, half of the TB caseload 
came from the high burden sub-districts, Khayelitsha, Nyanga and Oostenberg. Athlone, South 
Peninsula and Tygerberg West sub-districts achieved cure rates of above 80%.15 Site B clinic 
in Khayelitsha treated over double the number of TB patients than any other clinic in Cape 
Town and still managed to achieve a cure rate of 72% which is 2% higher than the district 
average.15 High cure rates can be achieved in spite of huge caseload. In 2007  Khayelitsha was 
reported to have five high burden clinics accounting for 11% of the provincial burden.11 
Klipfontein, Eastern and Northern had three high burden clinics each while Mitchell’s Plain 
and Western had two high burden clinics.11  
 
The success of the TB control programme can be monitored by the assessment and review of 
treatment outcomes for patients that are initiated on TB treatment. Approximately 87% of 
persons with TB are managed by public sector services in Cape Town.15  
 
TB/HIV co-infection  
 
The HIV/AIDS epidemic has impacted on the incidence of TB.16 It has been shown that HIV- 
positive individuals have about a 10% annual risk of TB disease or active TB and a more than 
30% life time risk of developing TB disease.11 In South Africa HIV prevalence in incident TB 
cases were estimated at 63% in 2012 or 330 000 of persons put on treatment for new TB were 
co-infected with HIV.1 Co-infected patients have an increased risk of morbidity and mortality 
with TB being the leading cause of mortality among HIV infected patients in TB endemic 
countries, even in the presence of access to antiretroviral therapy (ART).17 In 2012 in South 
Africa the mortality rate was 168/100 000 for co-infected persons while the mortality in 
uninfected persons was 59/100 000 showing that HIV is associated with increased mortality.1 
HIV infection increases the risk of reactivation of latent TB 20-fold with a much higher risk in 
patients who have clinically advanced HIV disease.18  The HIV prevalence in Cape Town in 
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2012 was 5.2%, the lowest recorded among metropolitan municipalities.19 The HIV status of 
84% of TB patients was known and 65% of these patients were co-infected with HIV.19 
 
Monitoring the distribution of TB in adults, the way in which TB was diagnosed, the presence 
of HIV co-infection as well as the outcomes is essential for understanding the effectiveness of 
TB control programmes20 and identifying specific high risk groups that should be targeted.21 
Furthermore, the success of the TB control programme can be monitored by periodic 




To describe the distribution of tuberculosis in persons with treatment outcomes at public sector 
clinics and the risk factors associated with TB treatment outcomes in the Western Geographic 
Service Area (GSA) of the Cape Town Metropole District.  
 
Purpose 
The purpose of this study was to describe the characteristics of persons placed on TB treatment 
at public sector clinics and to describe factors associated with treatment outcomes so that 
appropriate interventions could be identified and implemented at these services.  
 
Specific objectives 
To describe the characteristics of TB patients placed on TB treatment at public sector facilities 
in the Western GSA of Cape Town according to the following variables:  
 Demographics  
 Patient category (new or retreatment)  
 Disease classification pulmonary, extra pulmonary or both  
 HIV status  
 Tuberculosis Treatment outcome  
To identify factors associated with TB treatment outcomes in the adult population placed 







This will be a secondary analysis using quantitative research methods and data collected in 
electronic TB registers (ETR.net) of adults placed on TB treatment at public sector facilities 
for the Western GSA Cape Town. This will be cross sectional study. ETR.net is an electronic 
TB register designed for TB/HIV surveillance used to monitor and evaluate the TB/HIV 
programmes. It is implemented at sub-district, district and provincial levels in all provinces of 
South Africa. It was implemented in all sub-districts in Cape Town in January 2003, with data 
backdated to July 2002. All patients initiated on TB treatment are monitored on ETR.net which 
captures patient-based information at the district level directly from paper TB registers and 
enables staff to monitor and evaluate TB programmes. At data entry level paper TB registers 
are checked for completeness and accuracy before entering data on ETR.net. The data is 
progressively entered throughout the treatment period and contains the following information; 
basic demographics, date of treatment initiation, treatment type (new or previously treated), 




The Western Cape Department of Health and the Cape Town Health Directorate provide free 
TB treatment in primary health facilities in Cape Town. The Cape Town Metro is divided into 
eight sub-districts. The sub-districts are Southern, Mitchell’s Plain, Klipfontein and Western 
(Western Geographic Service area) and Khayelitshya, Tygerberg, Eastern and Northern 
(Eastern Geographic Service area). We will use data from the Electronic TB register (ETR.net) 
collected from the Western GSA on patients who initiated treatment from June 2011 to July 
2012. 
 
 Study population  
 
The study population will comprise all TB patients aged 15 and above, inclusive of both new 
and retreatment cases in the TB registers and who have a treatment outcome. TB patients should 
have initiated treatment in the Western GSA of Cape Town Metropole between June 2011 and 
July 2012.  
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Inclusion and Exclusion criterion 
Inclusion 
 All TB patients 15 years of age and older  
 With a final treatment outcome. 
 Initiated on treatment between June 2011 and July 2012 
Exclusion 
 Patients aged less than 15 years will be excluded. 
 Patients who were transferred out to other treatment centres or who were still on TB 
treatment at the end of the study period will be excluded because we cannot determine 
their treatment outcome.  
 We will also exclude those who were transferred in because we will not have complete 
information on these patients. 
Study size 
The Cape Town Metro is divided into eight sub-districts. The sub-districts are Southern, 
Mitchell’s Plain, Klipfontein and Western (Western Geographic Service area) and 
Khayelitshya, Tygerberg, Eastern and Northern (Eastern Geographic Service area). TB patients 
from the Western GSA, initiated on treatment from June 2011 to July 2012 with a treatment 
outcome will be included in this study. 
Data management  
 
Data from the ETR.net will be cleaned to ensure that only the needed data is analyzed. The 
cleaning will be done under the guidance of the supervisor ensuring that the date is double 
checked by the investigator and rechecked by the supervisor. The following variables will be 
analyzed;  
 Age and sex  
 Prevalence of TB for the study period stratified by sex and age stratified by sub-
district 
 Site of tuberculosis whether Pulmonary or Extra-Pulmonary TB 
 Retreatment categories 
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o Relapse (Pulmonary) 
o Retreatment after failure (Pulmonary) 
o Treatment after default 
o Other retreatment cases 
 TB/HIV co infection 




Statistical analysis will be done using the STATA version 12 for windows after importation of 
data from Microsoft excel. TB case notifications will be established for each sub-district and 
incidence rates will be calculated using data from the 2011 census. Baseline characteristics and 
treatment outcomes will be identified for the study population. Associations will be examined 
between characteristics such as age, sex and HIV status, patient treatment category and 
treatment outcomes using statistical tests such as chi-square test or fisher’s exact test and 
measures of association. A P-Value of < 0.05 will be considered significant. All continuous 
variables will be described using means and standard deviations while categorical variables 
will be described using counts and proportions.  
 




The study is from a setting with a high burden of TB disease and the large number of patients 





There may be missing or incomplete data that cannot be corrected since the study is using 
secondary data and we cannot go back to the original clinical records. The exclusion of those 





Ethical and legal consideration 
 
Human Research Ethics Committee 
 
The protocol will be submitted to the Human Research Ethics Committee of the Faculty of 
Health Sciences of the University of Cape Town for approval. Data from the ETR.net will only 
be analyzed after ethical approval is granted. Permission to use the data was provided by the 
Research Section of the Health Department of the Western Cape and the database for the 
Western GSA was provided by the TB programme.   
 
Privacy and Confidentiality 
 
The database that will be used for the analysis will not contain any names nor addresses. Special 
identifiers will be used. Only aggregated information will be reported. Access to information 
and data of the study will be restricted to research members only.  
Risk and benefits 
 
There are no risks anticipated for TB patients by the use of data from ETR.net. Although there 
are no direct benefits to TB patients information gained from the study will help in the control 
of TB and the management of TB patients.  
Resources 
 
There is no budget requested for this study. 
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Table 1: Variables 
Variable Variable type  
Registered TB patients Discrete Count 
HIV status Categorical Positive or Negative 
Treatment outcome Categorical C, TC, DF, F, D, TF, M 
Sex categorical, binominal Male or Female 
Patient category Categorical RC, RF, RD, OR 
Patient treatment regimen Categorical 1. New, 2. retreatment,  
End of Treatment smear 
conversion results 
 New case (end of six months) 
Retreatment case (end of 8 
months) 
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Reporting of results (including tables and figures) 
 
Table 1:  TB proportions by age groups 









   
Table 2- TB treatment outcomes 
Dummy tables 
Treatment outcome Frequency Percentage 
Completed   
Cured   
Defaulted   
Died   
Failed   
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Tuberculosis (TB) remains one of the most widespread infectious diseases worldwide and it 
has been exacerbated by the HIV pandemic. Although there is effective therapy for TB, it still 
poses a major health problem and it remains a major cause of morbidity and mortality in 
developing countries. According to the WHO, the recent intensive efforts to improve the 
collection and reporting of data on TB have shed new light on the epidemic, revealing that 
there are almost half a million more cases of the disease than previously estimated. The WHO’s 
Global Tuberculosis Report 2014, shows that 9 million people developed TB in 2013, and 1.5 
million died.1 
The TB epidemic has been driven by the epidemic of HIV. Patients with both HIV and TB 
have increased risk of morbidity and mortality with TB being the leading cause of mortality 
among HIV infected patients in TB endemic countries in Africa, even in the presence of access 
to antiretroviral therapy (ART).2  
According to the WHO, the life time risk of developing tuberculosis (TB) is estimated to be 
between 26 and 31 times greater in people living with HIV than among those without HIV 
infection. In 2013, there were 9 million new cases of TB, of which 1.1 million were among 
people living with HIV. 
HIV infection increases the risk of reactivation of latent TB 20-fold3 with a much higher risk 
in patients who have clinically advanced HIV disease.4 There is also a high risk of recurrent 
disease especially in patients with a low CD4 cell count, with exogenous reinfection accounting 
for approximately two thirds of recurrent disease on the South African gold mines.5 
 
South Africa is one of the African countries that has the highest burden of TB. The estimated 
incidence of tuberculosis disease was 1 003 cases per 100 000 population in South Africa in 
2012.6  TB is responsible for 5.4 % of total Disability-adjusted life years (DALYS) of the 
burden of disease in South Africa.7 In 2012 in South Africa 296 996 new cases of TB were 
notified.8 Of the new cases 40% (119 898) were sputum smear positive, 21% (63 210) were 
smear negative and 24% (71 421) did not have a smear or the result was not known, while 14% 




Western Cape Province  
 
In the Western Cape Province of South Africa, TB is a major health problem and in 2012 
together with HIV and interpersonal violence, accounted for the largest proportion of premature 
mortality (HIV/AIDS; 12.0%, interpersonal violence; 9.2% and tuberculosis; 7.4%).9 
Historically, the province has experienced an increased TB incidence rate particularly in the 
coloured population.10 The coloured population accounted for 42.4% of the Cape Town 
population in 2011. .11  
Despite the increase in TB incidence there has however been a stable annual risk of infection 
in this high risk group.11 The average annual risk of infection calculated as an average 
prevalence of infection, approximates the incidence of infection and indicates the extent of 
transmission in a community.12 This could reflect the high prevalence observed in the coloured 
community.12 Claassens et al attributed the increase in TB incidence to the inability of the 
health services to reduce new infections in the communities.11  
Yach reported that in the Western Cape late presentation for health care, led to an increase in 
the infectious pool and this was aggravated by overcrowding and poor social conditions. There 
were also other risk factors for TB disease such as poor nutritional status, alcoholism and 
unemployment. Poor patient compliance and several health service impediments resulted in a 
large number of patients not being held on treatment until cure.13  
Although the province has a higher incidence than the national average it leads the country in 
its progress through the TB strategy. The cure rate for new smear positive TB is 80.5%, the 
highest TB cure rate achieved in South Africa.14 The World Health Organization target is 85%. 
Tuberculosis treatment 
The tuberculosis treatment programme are aims to;  
 Cure patients of the infection and to restore their quality of life.  
 prevent death or prolonged ill health due to TB 
 prevent the relapse of TB 
 reduce transmission of TB to others 




The WHO developed TB Treatment Guidelines and recommendations that TB control 
programmes in most countries have adopted. The strength of TB control remains in establishing 
and managing standardized treatment across the country for all adult and paediatric TB cases. 
It is advised that in all cases, WHO guidelines on patient categorization and management are 
followed.8 South Africa is currently using the 2013 treatment guidelines. 
Diagnosis, treatment and outcome of TB patients are collected in the TB register. Information 
collected in the TB register can help improve the management of new patients.  The outcome 
categories follow the guidelines set by WHO and include the treatment outcomes; cured, 
treatment completed, treatment failure, died, defaulted or transferred out.8  
Monitoring the distribution of TB in adults, the way in which TB was diagnosed, the presence 
of HIV co-infection as well as the outcomes is essential for understanding the effectiveness of 
TB control programmes15 and identifying specific high risk groups that should be targeted.16  
Search Strategies 
PubMed, MEDLINE, Scopus, MeSH database and journals in NCBI database were searched 
for studies on treatment outcomes for patients commenced on TB treatment. The key words 
included tuberculosis or TB and words related to treatment or therapy and outcome(s).  
Key words: Tuberculosis, outcomes, risk factors, determinants, treatment  
Study selection 
This review included original reports which included primary and secondary studies. All 
reviews were excluded since the quality of the studies that are included in the reviews could 
not be accessed. Cross sectional studies that used TB registers as a source of data, as well as 
prospective cohort and retrospective studies that were either clinic- or hospital-based, were 
included. 
Purpose 
To perform a literature review on TB treatment outcomes and their determinants. 
Review objectives 
 
The purpose of this literature review was to identify risk factors associated with TB treatment 
outcomes in adults initiated on TB treatment. There are various factors that influence the 
possible treatment outcomes of patients initiated on TB treatment and these can be patient 
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related factors such as age and sex of the patient, the adherence pattern to prescribed treatment, 
alcohol use during treatment, education status as well as socio-economic status of the TB 
patients and whether coinfection with HIV is present. Other factors could be treatment related 
which include prior TB treatment and treatment services. 
 
Summary of literature  
Patient related factors 
 Age and sex  
Age and sex have been found to be associated with TB outcomes in a number of studies. 
Fatiregun et al. in 2009 showed that sex was associated with poorer treatment outcomes in a 
cohort of sputum smear-positive pulmonary TB patients. This study was done at tuberculosis 
treatment centres in Ibadan, Nigeria and showed that being male was a significant risk factor 
for a poor treatment outcome compared to being female.17 Similarly a study of 756 TB patients 
at a referral Hospital in northwest Ethiopia from 2010 to 2012 showed that death and defaulting 
was higher in females than in males and that older patients, rural residents and patients with 
EPTB were significantly less likely to have a successful outcome.18 
 
Adherence to TB treatment 
 
There were a number of studies on factors associated with adherence to medication. Adherence 
to treatment is defined as ingestion by patients of at least 90% of the expected dose. When 
patients are non-adherent, treatment is not taken according to the prescribed dosage or period 
resulting in poor treatment outcomes.  
Studies reported many predictors for non-adherence to TB treatment. These include sex of the 
patient, age, poverty, severe psychological stress and alcohol use. Other predictors were 
availability of DOT and the different ways in which it is provided, the presence of co-infections 
and use of traditional medicines. Proper follow up of defaulters by health care worker TB trace 
teams was shown to encourage adherence.  
Predictors of non-adherence to TB treatment which included being male, poverty, having more 
than one chronic condition, severe psychological stress and alcohol misuse were supported in 
a cross-sectional survey conducted in 2013 in 14 public sector primary health care clinics in 
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Northern Cape, Eastern Cape and KwaZulu-Natal of 3107 participants with new TB of whom 
55.9% were co-infected with HIV.19  
Directly Observed Therapy (DOT) has been advocated to ensure that patients adhere to 
treatment. Clinic approved observers witness the ingestion of TB treatment and this has had a 
great impact on reducing treatment default rates.20, 21   
A study in 2012 in Tanzania from 93 health facilities in four districts (rural and urban) found 
that 95% of adult patients who opted for home-based treatment under the patient centred TB 
treatment (PCT) approach adhered to the treatment regimen. There was no decline in adherence 
when symptoms resolved in contrast to the conventional daily Health Facility-DOT approach 
where adherence declined.22 The same study found that patients with treatment supporters more 
than 15 minutes walking distance away, were less likely to adhere to treatment than those 
staying in the same home.22  
DOT is one component of the DOTS strategy to control TB. Where the DOTS strategy had 
been well implemented success rates exceeding 95% have been attained.23 Case detection and 
cure rates are the main indicators of a well implemented DOTS programme, with global targets 
of 70% detection and 85% cure rate. Elzinga et al in 2004 reported that in high HIV prevalence 
populations such as those in Southern Africa TB incidence was increasing by 10% per year 
without the implementation of DOTS strategy. However a model predicted that attaining 70% 
detection and 85% cure rate would result in the trend being reversed from a 10% increase to a 
4% decrease in TB incidence.24 In order for the programme to work efficiently and effectively 
health providers must be fully engaged, 23 links must be built between public and private 
practitioners, health services must be available to all, 24 and global support provided to 
countries trying to reach their TB prevention, and treatment aims.25  
Another study in 2007 in Bangkok investigated whether different ways of providing treatment 
support affected adherence including centre-based DOT, family-based DOT, self-administered 
treatment (SAT), centre-based DOT plus SAT and centre plus family-based DOT.26 The centre- 
plus family-based DOT and family based DOT had significantly higher success rates when 
compared with centre-based DOT. Centre-based DOT plus SAT was almost five times more 
effective than centre-based DOT while SAT was the least successful.26  
Lack of adherence to medication and treatment interruption were associated with death and 
relapse in a number of studies.27, 28  In south-western Nigeria a retrospective review of the TB 
register from 2008 – 2011 showed that  more treatment interrupters than those who adhere to 
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treatment died (54.1% versus 14.9%) and more relapsed (14.3% versus 3.4%).27 Lack of 
adherence was shown to lead to TB Treatment failure in Burkina Faso, in a case control study 
conducted among pulmonary TB patients who began TB treatment in 2009 to determine risk 
factors for treatment failure.29 Failure to take TB drugs for more than 14 consecutive days was 
a significant risk factor together with a positive sputum smear after two months of treatment, 
existence of comorbidity and use of traditional medicines or herbs.29 
A historical cohort study of TB patients from 2004 until 2006 in Rio de Janeiro found that 
patients who self-administered treatment achieved a 72% cure rate.30 Younger age and being 
alcoholic were significantly associated with treatment default.30 
In 2004 a study in South Africa described adherence to standardized TB treatment and the 
effect of DOT on treatment outcomes. Patients who received partial DOT had an increased risk 
of an unfavourable outcome including death, treatment failure and default as well as patients 
who received DOT during either the intensive phase or the continuous phase.31 
Bronner et al assessed the impact of the TB Tracer Project on treatment outcomes among TB 
patients with smear positive TB and registered in the Electronic TB Registry from 2007- 2009 
in South Africa. Health care worker TB tracer teams traced TB patients who had interrupted 
treatment or had missed a clinic appointment to obtain a sputum sample which was used to 
assess the smear status for TB. The study used sub-districts as the unit of analysis, with each 
designated as either tracer (standard TB programme plus tracer project) or non-tracer (standard 
TB programme only). For all provinces combined, the percent quarterly change in proportion 
of TB treatment outcomes decreased significantly for default treatment outcomes among tracer 
sub-districts and increased significantly for successful treatment outcomes among tracer sub-
districts. 32 A significant decrease in the proportion of patients defaulting was observed for all 
provinces combined over the time period comparing tracer and non-tracer sub-districts.32  
 
Patient-related factors were also reported in a prospective cohort from 2005-2012 to be 
predictors of treatment outcome in South Korea.33 Predictors of unfavourable outcomes at end 
of treatment (EOT) and end of study (EOS) in new or previously treated tuberculosis patients 
were identified. Both patient factors (diabetes status, age, BMI) and disease factors (history of 
multiple previous treatment episodes, MDR-TB) were significantly associated with treatment 
outcomes. Diabetes mellitus MDR-TB were significantly associated with poor treatment 
outcomes and relapse.33 Those aged ≥50 years were more likely to have an unfavourable 
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outcome when compared to those aged 20-34 years. BMI ≥18.5 was negatively associated with 
cure .33 
TB and HIV co-infection 
 
Studies showed that HIV co-infection impacted on TB treatment outcomes. The optimal timing 
of ARV treatment of HIV infection was associated with better treatment outcomes. A study in 
Hong Kong from 1996 until 2009 showed that early ARV therapy in naive patients with 
tuberculosis was significantly associated with a more favourable outcome. However a higher 
proportion of patients initiated early experienced immune reconstitution inflammatory 
syndrome (22% vs 4%).34 This was thought to be due to the low median CD4 counts of 74µl 
(range 29-181 µl) in those initiated early. However there were no deaths attributed to immune 
reconstitution inflammatory syndrome. On the other hand, Oshi et al. in 2014 determined 
predictors of successful treatment outcomes in co-infected TB patients in two health facilities 
in Ebonyi State, Southeast Nigeria, during 2011 and 2012. Overall, 65.8% of patients achieved 
successful outcomes.35 The unsuccessful treatment outcomes were due to “default” (9.9%), 
“death” (19%), “treatment failure” (1.5%), and “transferring out” (3.8%).35 Receiving care at 
a public facility and non-initiation of antiretroviral therapy were significant independent 
determinants for an unsuccessful outcome.35  
 
Furthermore, only 53.4% of 219 co-infected patients had favourable outcomes, in a study in 
Malaysia in 2010 36 and unfavourable outcomes were significantly associated with intravenous 
drug use, not receiving antiretroviral therapy, lymphadenopathy and low serum albumin .36    
Service provision showed an impact on treatment outcome in co-infected patients in a study 
done from 2006 until 2009 in rural Mumbwa district, Zambia. TB treatment success rate 
improved significantly at sites that provided ART after the implementation of a mobile ART 
programme compared to non-ART sites.37 Rates of HIV testing in TB patients also increased 
at ART sites37. Scaling up ART services in rural health facilities through a mobile ART 
programme greatly improved anti-tuberculosis treatment outcomes. 
Alcohol use 
 
Peltzer et al. in 2014 assessed factors associated with TB treatment failure, death and default 
in 40 public primary health care facilities in three districts (Siyanda in the Northern Cape, 
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Nelson Mandela Metro in the Eastern Cape, and eThekwini in KwaZulu-Natal). This 
prospective study showed that 70% of TB patients were either cured or had completed their TB 
treatment by the end of 6 months. Participants who lived in a shack or traditional housing, those 
previously treated for TB and those residing in the eThekwini district  were significantly more 
likely to fail treatment, die or default.38 Mukinda and others in 2012 also showed that the 
increase in rifampicin mono-resistant TB (RMR-TB) in the Cape Winelands-Overberg region 
was significantly associated with alcohol abuse .39 
 
Finlay et al. in 2012 also showed that drinking any alcohol during TB treatment was 
significantly associated with defaulting treatment in South Africa.40 The abuse of alcohol, 
being homeless and previous imprisonment were significantly associated with an unfavourable 
outcome in new pulmonary TB cases in Kazakhstan from 2000 to 2002.41 
 
Socio-economic status and economic support 
 
Studies showed that socio-economic factors affect TB treatment outcomes with the poor more 
likely to have an unfavourable outcome.30 A cluster randomized controlled pragmatic trial in 
2013 in a resource-limited setting in KwaZulu-Natal, South Africa tested the feasibility and 
effectiveness of delivering economic support to patients with pulmonary TB in a high-burden 
area. KwaZulu Natal had the second highest poverty rate in the country and more than half the 
population fell below the poverty line.42 In the intervention clinic, TB patients were offered a 
monthly voucher of ZAR120.00 which was redeemed at local shops for foodstuff.  Vouchers 
were provided until the completion of TB treatment. Patients in control clinics received the 
usual TB care. The economic support did not significantly improve treatment outcomes.42 
Finlay et al. found that TB patients who felt that food provisions could have helped them finish 




Early detection of TB depends on good health seeking behaviour and knowledge of the signs 
and symptoms of TB as well as the availability and accessibility of services. A study in 2014 
in Rajshahi City, Bangladesh revealed that patients with pulmonary TB had greater knowledge 
about the symptoms, transmission, prevention and management of TB than those who had 
extra-pulmonary TB. Sex, age and educational status were also significantly associated with 
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level of knowledge. Female TB patients were significantly less likely and patients aged 21-35 
years more likely to know about the transmission and prevention of TB.43 Individuals with 
higher education and from urban areas were better informed about the symptoms and signs of 
TB disease.43 A study in Nigeria by Fatiregun et al. also reported that poor knowledge of 
tuberculosis resulted in a higher risk of poor treatment outcomes compared to those with a good 
knowledge.17  
 
Treatment related factors 
Studies showed that a number of treatment-related factors were associated with TB outcomes. 
These include prior TB treatment and the integration of TB and HIV services. 
Retreatment of TB 
 
Retreatment may result from reactivation of persistent organisms after insufficient treatment 
of TB or from exogenous reinfection with TB.44 A study in 2012 showed that episodes of 
retreatment TB between 2001 and 2010 in a high HIV and TB burden community of Cape 
Town were linked to first-episode treatment outcomes, HIV status and ART use. The study 
included 564 retreatment cases and showed that among HIV-negative patients, retreatment TB 
was predominantly due to reactivation following poor initial treatment outcomes while among 
HIV-positive patients re-infection TB was more common, particularly among those on ART.44 
A study in Turkey in 2013 also showed that persons with an unfavourable TB outcome were 
significantly more likely to have had a previous history of TB. Patients with a history of 
interrupted treatment were 10 times more likely to default and patients with prior treatment 
failure were 17 times more likely to have treatment failure.28 This was supported by Choi et al. 
in 2014 who identified previous treatment as a predictor of unfavourable outcomes and patients 
with more than 2 or more than 4 previous treatment episodes were significantly more likely to 
have an unfavourable outcome.33 
 
Akpabio et al. identified treatment outcomes in hospitalised TB patients who were followed 
between from 2005 till 2007 in Ermelo in South Africa.  More than two-thirds of the patients 
had completed TB treatment previously, and almost three-quarters (74%) of the patients had 




Integrated HIV/TB treatment services 
 
Studies showed that linking TB and HIV treatment and prevention programmes improved the 
diagnosis, treatment and outcomes for patients who were co-infected with HIV.46 Ikeda et al. 
showed co-infected patients at TB/HIV services in Guatemala were more likely to receive ART 
once services had been integrated (22% prior to versus 72% post integration) and they were 
significantly less likely to die.46 Another study in Uganda showed that, integration of HIV and 
TB services resulted in improved TB outcomes and earlier ART initiation. More patients were 
started on ART during TB treatment (94% vs 78%) and mortality decreased in an integrated 
TB/HIV care centre when compared to the pre-integrated service.47 
In 2013 Schulz et al. evaluated the outcomes of co-infected patients starting ART in a TB 
hospital in the Western Cape, South Africa. After the hospital stay, one group of patients 
received their treatment at an integrated TB and ART service while the other group received 
treatment from different providers. The vertical care model had significantly more 
unfavourable TB (28.7% vs. 5.9 %) and ART outcomes (30.1% vs. 7.4%) than the integrated 
care model.48 
Ansa et al. assessed the impact of TB/HIV integration on TB treatment outcomes in Ghana. 
The study showed that TB/HIV integration significantly improved TB treatment success. In a 
before-and-after study in three hospitals the TB treatment success rate was 50% prior to, and 
69% after integration.49 Conversely in 2014 a study showed that there was no significant 
difference in treatment outcomes for newly registered, adult TB patients, including a subset of 
co-infected patients, at 13 integrated ART/TB primary healthcare facilities (PHC) compared to 
four single-service PHC facilities in 2009 and 2010. Integration was not associated with lower 
TB mortality and defaulter rates.50  
In 2010 Howard et al. showed that successful integration of TB and HIV services in resource 
constrained settings was possible, although programmatic, infrastructure and staffing 
challenges still existed.51 In Kenya a report on successes and challenges in an integrated 
TB/HIV clinic in a rural area with a resource limited setting also showed that the yearly odds 
of treatment success improved by 20% after the integration of TB/HIV services in resource-




Reviews of routinely collected TB indicators 
 
According to the WHO, treatment outcome is an important indicator for monitoring TB 
programmes. Maimela described the performance of the TB control programme in the Eastern 
Cape Province by evaluating treatment outcomes from 2003 to 2005.53 A cure rate of 39.7% 
for new smear positive patients in 2005 was reported. The national target was 70% and this 
was reached by only one district. Successful treatment outcomes were below the 85% threshold 
suggested by the WHO.53 Defaulting from treatment was a major challenge.54 The study found 
that a lack of human resources was one of the major challenges. 
 
Gafar et al. reviewed data from ETR.net from 2006 to 2010 in Limpopo Province by selecting 
a random sample of 1200 records.54 New treatment cases, patients who received treatment at 
mine health facilities or those treated with regimen 3 had more successful treatment outcomes. 
Patients aged 22–55 years, patients with a history of defaulting and those who had received 
treatment at community health centre or village health facility were more likely to default on 
treatment. Patients that had failed treatment before, those that had received treatment at the 
hospital or mobile health facilities or were treated with regimen 2 experienced treatment failure 
more often. The testing rate for HIV amongst TB patients increased substantially from less than 
1% in 2006 to 68% in 2010. This increased the number of known co-infected patients who 
initiated ART during the study period. Integrated HIV/TB services had also improved during 
the study period.54 
 
Conclusion 
TB continues to be a major contributor to morbidity and mortality globally and the HIV 
epidemic has had a major impact on TB prevalence. In the Western Cape, although the rate of 
co-infection is lower than the national average, TB rates are extremely high and a major 
contributor to the burden of disease.  
The literature review identified patient-related and treatment-related factors associated with TB 
outcomes. Patient related factors such as age, sex, adherence to medication, co-infection with 
HIV and socio-economic status were identified as important risk factors for TB outcomes. 
Other factors were related to treatment and these were prior TB treatment and integration of 
TB and HIV services. 
35 
 
Treatment outcomes were associated with adherence patterns. Poor adherence is related to a 
number of factors. DOT has been recommended to ensure that TB patient take their drugs as 
prescribed. Studies showed that a combination of centre-based and family-based DOT yielded 
more successful treatment outcomes. 
A number of interventions that improved outcomes have been identified. Integrated TB and 
HIV services have been shown, when well implemented, to improve treatment outcomes 
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In the Western Cape Province of South Africa, tuberculosis (TB) is a major health problem and 
in 2012 accounted for 7.40% of premature deaths. The Province has also experienced an 
increase in TB incidence in the past 20 years. 
Objectives 
The aims of the study were to describe the distribution of tuberculosis and identify risk factors 
associated with TB treatment outcomes in public sector tuberculosis facilities in the Western 
Geographic Service Area of the Cape Town Metropole District. 
Methods 
A cross sectional study was conducted using data collected in electronic TB registers from June 
2011 to July 2012. Patients initiated on TB treatment aged 15 years and above with a known 
treatment outcome were included in the study.  
Results 
The study included 10 251TB patients registered during the study period who  had a final 
treatment outcome and 55.35% (5 674) were males. The mean age was 36.0 years and 72.20% 
(7398) were new cases. Most patients had pulmonary TB (83.21%). Almost half of the patients 
(49.62%) were co-infected with HIV. 
Of the 10 251 cases, 47.02% (4 820) completed treatment, 37.43% (3 837) were cured, 8.67% 
(889) defaulted, 5.18% (531) died and 1.70% (147) failed treatment. There was a significant 
association between treatment outcome and sex, disease classification, treatment regimen, HIV 
status and patient category. 
Conclusion 
A high proportion of incident TB cases had previously been treated for TB.  Overall treatment 
outcomes were poor. Unfavourable treatment outcomes were more common in men, those with 





Tuberculosis (TB) is still a major health problem internationally. It causes morbidity each year 
in millions of people and is the second leading cause of death from an infectious disease 
worldwide, following Human Immunodeficiency Virus (HIV). According to the World Health 
Organization (WHO) Tuberculosis report 2013, in 2012 there were 8.6 million new cases of 
TB disease and 1.3 million TB deaths.1   Most TB cases including deaths due to TB occurred 
in men but the burden of disease among women was also high.  
The World Health Organization (WHO) recommends the DOTS programme in the fight against 
the spread of TB. The programme consists of five components; political commitment, case 
detection by sputum microscopy, standardized short-course chemotherapy, sustainable drug 
supply and standardization of recording and reporting.2 South Africa is among the countries in 
Africa that have the highest burden of TB3 and has adopted the DOTS programme in its national 
TB programme and makes every effort to reach a 70% detection rate and 85% treatment 
completion rate required for an effective fight against the spread of TB.2 In 2012 the WHO 
reported that South Africa had an estimated incidence of 1003 cases per 100 000 population.1 
In the same year, 296 996 new cases of TB were notified. Of the new cases 40% were smear 
positive, 21% were smear negative and 24% did not have a smear or the result was not known, 
while 14% had extra pulmonary TB.1 There were 52 586 retreatment cases, who had previously 
received treatment for 1 month or more. Of the retreatment cases 51% were relapse cases, 6% 
were treatment after failure, 15% were treatment after default while 28% had another reason 
for retreatment.1 In 2012 in South Africa, HIV positive incident TB cases were estimated at 
631 per 100 000 population.1    
 
In the Western Cape Province of South Africa, TB is a major health problem and in 2012 
accounted for 7.4% of premature mortality.4 TB is a major contributor to the burden of disease 
in Cape Town with a 66% increase in the number of TB cases notified between 1997 and 2003.5 
The HIV/AIDS epidemic has also impacted on the incidence of TB.5The HIV prevalence in 
Cape Town in 2012 was 5.2%, the lowest recorded among metropolitan municipalities.6 The 
HIV status of 84% of TB patients was known and 65% of these patients were co-infected with 
HIV. 
The Western Cape Department of Health and the Cape Town Health Directorate provide free 
TB treatment in primary health facilities in eight sub-districts in Cape Town. Despite the 
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reported increase in TB incidence in Cape Town the TB Control Programme aims to identify 
80% of people who have TB and to cure them at the first attempt.5 The success of the TB 
control programme can be monitored by the assessment and review of treatment outcomes for 
patients that are initiated on TB treatment.  
Treatment follows the treatment guidelines recommended by the WHO7, TB treatment is given 
for six to eight months depending on the regimen initiated.  TB Treatment is provided in two 
phases. During the intensive phase four drugs in combination are given for five days a week, 
for two to three months. The second phase is the continuation phase, in which two drugs are 
given for five days a week, for four to five months. New TB patients are treated for six months, 
while retreatment patients are treated for eight months. Sputum tests are taken again after two 
months on treatment to check for progress, and at five or seven months to confirm whether the 
patient is cured. 
The Western Cape Department of Health has adopted the WHO's DOTS strategy which 
includes directly observed therapy (DOT) to ensure patients adhere to treatment and this has 
been implemented in most clinics in the Western Cape. An important element of the strategy 
is the support and encouragement offered. TB clients are either observed taking their treatment 
at the clinic or at community level, by non-governmental organisations (NGOs) using 
volunteers as "treatment supporters" for the entire treatment period.5 An integrated TB and 
HIV/AIDS strategy is also used where co-infected patients are treated for both TB and HIV 
and provided with Cotrimoxazole prophylaxis.8   
Monitoring the distribution of TB in the adult population, the way in which TB is diagnosed, 
the presence of HIV co-infection as well as the treatment outcomes is essential for 
understanding the effectiveness of the TB control programme9 and aid in identification of 
specific high risk groups that can be targeted in the fight against TB spread.10 According to the 
WHO, treatment outcome is an important indicator for monitoring TB programmes.2  
Cape Town has a high burden of TB, with cure rates ranging from 72% to 80%.5 Continued 
monitoring of these cure rate will provide an assessment and review of treatment outcomes for 
patients that are initiated on TB treatment. 
The Cape Town Metropole District is managed as two service areas. This study aimed to 
describe the distribution of TB at public sector TB facilities and to identify risk factors 
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associated with treatment outcomes in the Western GSA of Cape Town which consisted of 4 
sub-districts namely, Klipfontein, Mitchell’s Plain, Southern and Western. 
Methods 
A cross sectional study was conducted using data collected in electronic TB registers (ETR.net) 
for the Western GSA Cape Town from June 2011 to July 2012. ETR.net is used to monitor and 
evaluate the TB programme as it allows for cohort analysis matching case finding, smear 
conversion, treatment outcome reports as well as HIV testing and services for TB patients. The 
register provides easy and convenient collection, compilation, and analysis of TB data on a 
continuous basis. The register provides information on the demographics of persons on TB 
treatment and the outcomes. The categories of treatment outcome were cured (positive 
bacteriology at initiation and negative at completion), treatment completed (in the absence of 
bacteriological confirmation), treatment failed (positive bacteriology at the end of treatment), 
died and defaulted (treatment interrupted for more than 2 consecutive months).   
A favourable treatment outcome included those who were cured or completed TB treatment, 
while an unfavourable outcome included those who defaulted, died or failed treatment. This is 
also known as the treatment success ratio.  Factors investigated to determine if they are 
associated with outcome included sex, category of patient, type of TB and HIV status. 
The protocol was approved by the Human Research Ethics Committee of the Faculty of Health 
Sciences of the University of Cape Town. All data were anonymised.   
 
Statistical analysis was completed using the STATA version 14. Patient’s characteristics were 
summarized using proportions. The Chi square test was used to examine the influence of 
variables on treatment outcomes.  
Results  
There were a total of 25 854 registered TB patients from the 4 sub-districts and 15 242 (59.0%) 
TB patients were over 14 years of age. Of the total registered TB patients 32.1% were from 
Mitchell’s Plain, 26.9% from Klipfontein, 23.9% from Western and 17.1% were from Southern 
(Table 1).  
The overall TB incidence rate (case detection rate) among the 4 sub-districts was 1041 cases 
per 100 000 population, with Klipfontein having the highest TB incidence rate (1 811 per 100 
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000 population) and Mitchell’s Plain having the lowest TB incidence (745 per 100 000 
population). 
Only 67.3% (10 251/15 242) of patients above 14 years of age had treatment outcomes and of 
these patients with treatment outcomes, 32.8% patients were from Mitchells Plain, 26.8% from 
Klipfontein, 23.5% from Western while 16.9% were from Southern. Of the patients with 
treatment outcomes, 55.4% were males while 44.6% were females. Demographic and clinical 
data on these patients are shown in Table 2.  The mean age was 36.0 years (SD12.42 and range 
15 to 97 years). The mean age for females was 34.4 years while that of males was 37.4 years. 
Figure 1 shows the age distribution of the patients. 
The majority of cases were new cases (72.2%) and 71.8% received treatment regime 1. 
Retreatment cases after relapse accounted for 8.3%, retreatment after default for 2.6% and 
retreatment after failure accounted for 0.6%. Other retreatment case with unknown or 
undocumented previous outcome were 16.4 % (Table 2). 
The majority of the patients had pulmonary TB (83.2%) while 15.5% had extra-pulmonary TB 
and 1.3% had both types of TB (Table 2). There were more females with extra-pulmonary TB 
(51.9%) while more males had pulmonary TB (56.7%) as shown in Table 3.  
HIV test results were available for 99% of the TB patients and almost half of the patients 
(49.1%) were co-infected with HIV. CD4 results were available for 96.5% of the HIV-infected 
patients and the mean CD4 count was 221 cells/mmᵌ (range 0 to 1851). Of those who were HIV 
positive, 42.6% were on ART and 18.0% had been on ART before TB treatment was 
commenced. 
Of all the patients placed on TB treatment 10 251 (67.3%) had a final treatment outcome, and 
of these, 47.0% completed treatment, 37.4% were cured, 8.7% defaulted, 5.2% died and 1.7% 
(147) failed treatment. Table 4 shows a detailed summary of treatment outcomes for registered 
TB patients during the study period.  
Between June 2011 and July 2012 the treatment success rates of all registered TB patients with 
a final treatment outcome was 84.5%. The treatment success rate was 84.3% for patients with 
pulmonary TB, 85.8% for those with extra pulmonary TB and 80.8% for those with both 
pulmonary and extra pulmonary TB. New patients achieved a higher treatment success rate 
compared to those treated after failure (87.5% vs 66.1%, p=0.002) and subsequently patients 
placed on regimen 1 had a higher treatment success than patients on regimen 2 (87.5% vs 
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76.0%, p=0.000). Older TB patients (>65 years old) had a lower treatment success rate 
compared to those aged 25 to 35 years old (73.9% vs 84.5%, p=0.009) and co-infected patients 
also had a lower success rate compared to HIV negative TB patients (82.6% vs 86.6% 
p=0.000). There was no significant difference in success rate by sex (86.1% among females 
and 84.1% among males, P=0.692). Table 5 shows the variables associated with treatment 
outcome. 
The study showed that specific treatment outcomes were associated with age, sex, patient 
category, disease classification, HIV status and treatment regimen as shown in Table 5. Age 
category 15 to 24 years experienced higher defaulter rates compared to those 45 to 54 years 
(10.0% vs 7.3%, P=0.000). 
Although the sex of a patient was not associated with treatment success, more males had 
defaulted (9.8% vs 7.3%, P=0.000), nevertheless there was no difference between sexes in 
those that failed (1.8% vs 1.6%, P=0.742) and those that died (5.4% vs 4.9% P=0.315). Overall, 
there were more males compared to females among those with an unsuccessful treatment 
(60.2% vs 39.78% p=0.000). 
More patients with extra-pulmonary TB died compared to those with pulmonary TB (6.9% vs 
4.8%, P=0.000) and more patients with pulmonary TB defaulted from treatment (9.1% vs 5.9%, 
P=0.000). 
More patients on regimen two than regimen one had unfavourable outcomes including default 
(14.4% vs 6.5%, p=0.000) and died (6.8% vs 4.6%, P=0.000) but there was no significant 
difference in those that failed (2.4% vs 1.4%, P=0.123).  All the 8 (100%) TB patients on 
regimen 3 either completed treatment or were cured. 
More retreatment than new TB patients had unfavourable outcomes with 14.5% defaulting 
compared to 6.4% (P=0.000), 6.7% dying compared to 4.6% (P=0.000), however there was no 
significant difference in those failing therapy, 2.4% compared to 1.4% (P=0.105). The defaulter 
rate was similar amongst HIV-positive and HIV negative patients (8.6% vs 8.6%, P=0.801) but 
a larger proportion of co-infected patients died (7.0% vs 3.3% P= 0.000).   
Discussion 
This study found a high incidence of TB in all four of the sub-districts that comprise the 
Western GSA of Cape Town. This is aggravated by the high prevalence of HIV.5.11 More effort 
will be required to identify and cure all persons with TB to control this epidemic. 
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Most sub-districts in the Western Cape report a high caseload of TB patients.5,11 The four sub-
districts in this study had different caseloads with Mitchell’s Plain contributed the largest 
number of patients compared to the other sub-districts, although it had the lowest incidence 
rate. Mitchell’s Plain has been cited as one sub-district among others in the Western Province 
that has clinics with a high caseload and is characterised as a tuberculosis ‘hotspot’ 
geographical area. Theses TB ‘hotspots’ are areas with rapid urbanisation and high HIV 
prevalence.11 
This study on the treatment outcomes of patients places on TB treatment in the Western GSA 
of the Cape Town District where there is both a high burden of HIV and TB, showed a high 
proportion of retreatment cases of TB (almost 28%) and poor treatment outcomes. 
The proportion of retreatment cases is considered by many to be a measure of the quality of a 
TB control programme and poses a challenge to the control program. A study by Middelkoop 
et.al in 2012 also reported a high proportion of retreatment TB cases (28%) in Cape town.12  
As in another study done in Cape Town,13 our study showed that the rate of TB disease in a 
high prevalence area differs by age. Most TB cases were in the age group 25 to 44 years which 
are the productive years, indicating that TB may impact on the socio-economic conditions of 
the population. A study by Wood in 2010 in Cape Town showed that there were three peaks in 
TB incidence at 0-4 years, 20-24 years and 45-49 years of age. Our study which excluded 
children showed two distinct peak at 25 to 34 years and 35 to 44 years, 13 indicating an 
increased risk of infection with age and these are the age groups mostly affected with HIV 
infection.  
Other studies have reported that males are at an increased risk of a poor treatment outcome 
compared to females.14 In this study sex was associated with defaulting as in other reports and 
this may be attributed to the prevalence of high risk behaviours such as drug15 and alcohol 
misuse16 among men.  
Naidoo et al showed that males were less likely to adhere to treatment compared to females 
[OR 1.26 (1.07-1.48) P<0.001] resulting in unfavourable treatment outcomes.16 Sex and age of 
a patient were associated with treatment adherence in a Tanzanian study where female patients 
were two times more likely to adhere to treatment compared to male patients while patients 35 




The majority of patients with TB (99%) were tested for HIV. In 2003 the Cape Town district 
adopted an integrated approach to TB and HIV/AIDS at primary health care level with all TB 
patients being offered HIV counselling and testing (HCT) and subsequent initiation of ART 
for co-infected persons at the same facility.5 This allowed co-infected patients to access TB 
and HIV services at the same clinic and from the same health staff. Furthermore, 97% of co-
infected patients had a CD4 count result recorded and 92% were on co-trimoxazole preventive 
therapy. These results were similar to those reported for Khayelitshya, Cape Town in 2010 
where a decrease in the median time from the start of TB treatment to ART initiation was also 
observed.18  
Although the HIV rate among TB patients in this study was lower than the national average 
(50% versus 63% in 2012), 1 only 43% of co-infected patients were on ART during the study 
period. Various studies have documented the benefit of ART in co-infected patients.19 WHO 
guidelines recommend that all co-infected patients should be initiated on ART as soon as 
possible. The South African national TB treatment guidelines also require that all co infected 
patients be initiated on ART however, more than 50% of co-infected patients in this study were 
not on ART and the reasons for this should be explored.20 It has being shown that co-infected 
patients not on ART were 5 times more likely have an unfavourable TB treatment outcome.21  
  
The study showed that almost 9% of TB patients defaulted from treatment which is more than 
the WHO target of less than 5% and most defaulters were 15 to 24 years of age. Poor adherence 
to treatment results in patients remaining infectious longer and they are more likely to relapse 
or die. Targeted interventions to prevent defaulting in the younger age group are required. 
These could include the use of tracer teams and support to encourage compliance in this age 
group. Retreatment cases were also more likely to default, and particularly those who 
previously defaulted. Other studies have shown that patients with a history of interrupted 
treatment were 10 times more likely to default.22  
The overall mortality among TB patients in this study was 5%. The proportion of co-infected 
persons who died was double that of HIV negative TB patients. HIV co-infection has been 
reported by other studies to be associated with higher mortality among TB patients23 and that 
mortality has been shown to reduce when co-infected patients are cared for in a TB/HIV 
integrated service.24 A higher proportion of patients with extra-pulmonary TB died compared 
to those with pulmonary TB. Extra-pulmonary TB was found to be an independent predictor 





There were missing data that could not be corrected since the study used secondary data and 
we could not go back to the original clinical record. The study only included patients with 
treatment outcomes, and it is possible that those excluded may have had poorer outcomes.  
Conclusion 
The study showed that the incidence of TB is extremely high in the Western GSA of Cape 
Town and that treatment outcomes are poor and that there is a high rate of retreatment. There 
is a need to reduce the number of co-infected patients not on ART by following the WHO 
recommendations to prioritise ART for co-infected patients.  More deliberate efforts should be 
made to follow up TB patients who have previously had TB. We recommend enhanced 
supervision and monitoring, improved counselling and home visits, and early screening for TB 



















Figures and Tables 
 











TB incidence per 
100 000 population 
Klipfontein  6 957 (26.91) 4 063(26.66) 2 750(26.83) 384 189 1 811 
Mitchells Plain 8 285 (32.05) 4 951(32.48) 3 364(32.82) 1 112 650 745 
Southern 4 425 (17.12) 2 612(17.14) 1 727(16.85) 516 594 857 
Western 6 187 (23.93) 3 616(23.72) 2 410(23.50) 470 541 1 315 
Over all 
 
25 854 (100.00) 
 
 
15 242 (100) 
 
 






















15 to 24 25 to 34 35 to 44 45 to 54 55 to 64 65 to 74 75+












5 674 (55.35) 
4 577 (44.65) 
 
Age groups 15 to 24 years 
25 to 34 years 
35 to 44 years 
45 to 54 years 
55 to 64 years 
65 to 74 years 
Greater than 75 years 
1 809 (17.65) 
3 384 (33.01) 
2 701 (26.35) 
1 471 (14.35) 
   632 (6.17) 
   184 (1.79) 





2 750 (26.83) 
3 364 (32.82) 
1 727 (16.85) 
2 410 (23.50) 
Treatment type New 
Retreatment after Default 
Retreatment after Failure 
Retreatment after relapse 
Other Retreatment cases 
(unknown/undocumented previous 
outcomes) 
7 398 (72.17) 
   296 (2.62) 
     59 (0.58) 
    849 (8.28) 
1 676 (16.35) 





1 591 (15.52) 
8 530 (83.21) 
   130 (1.27) 
Treatment Regimen⃰ 1.2HRZE 4HR 
2.2HRZE 1HRZE 5HRE 
3.2HRZ 4HR 
7 357 (71.77) 
2 886 (28.15) 
       8 (0.08) 




5 016 (48.93) 
5 030 (49.07) 
     92 (0.90) 
   113 (1.10) 












With CD4 count 
No CD4 count 
2 145 (42.64) 
1 889 (37.56) 
   996 (19.80) 
 
 
4 856 (96.54) 
   174 (3.46) 
HIV-infected and on 





4 636 (92.17)   
 285 (5.66) 
 109 (2.17) 
⃰HREZ stands for isoniazid, rifampicin, ethambutol, pyrazinamide given daily for the number of months indicated 
53 
 


























Sex Disease Classification Total 
 
Both Extra-pulmonary Pulmonary 
 
Female 59(45,38) 826(51,92) 3692(43,28) 4577(44,65) 
Male 71(54,62) 765(48,08) 4838(56,72) 5674(55,35) 








Table 5. Variables associated with TB Treatment Success and unfavourable  TB treatment outcomes 
              













Patient category    Patient category   
New After failure    New Retreatment   
6476 (87.54) 33 (66.10) 0.002 Default 475 (6.42) 414 (14.51) 0.000 
     failed 106 (1.43) 86 (2.38) 0.105 
     Died 341 (4.61) 190 (6.66) 0.000 
          
Sex     Sex   
Male Female     Male Female   
4714 (83.08)  3943 (86.14)  0.692  960(60.23) 634(39.77) 0.000 
       
   Default 554(9.76) 335(7.32) 0.000 
    Failed 101(1.78) 73(1.59) 0.742 
      Died 305(5.38) 226(4.94) 0.315 
          
Age group    Age group   
25 to 34  65 to 75     15 to 24 45 to 54   
2861 (84.54) 136 (73.91) 0.009 Defaulted 181 (10.01) 107 (7.27) 0.000 
          
Disease Classification     Disease Classification   
Pulmonary 
Extra 
pulmonary     
Pulmonary Extra Pulmonary 
  
7187 (84.26) 1365 (85.80) 0.150 Died 413 (4.84) 110 (6.91) 0.000 
              
Treatment Regimen    Treatment Regimen   
Regimen 1 Regimen 2    Regimen 1 Regimen 2   
6437 (87.50) 2212 (75.96) 0.000 Defaulted 478 (6.50) 411 (14.24) 0.000 
     Failed 106 (1.44) 68 (2.36) 0.000 
     Died 336 (4.57) 195 (6.76) 0.000 
          
HIV status     HIV status   
HIV Negative HIV Positive     HIV Negative HIV Positive   
4344 (86.60) 4154 (82.59) 0.000 Defaulted 432 (8.61) 430 (8.55) 0.801 
      Failed 74 (1.48) 95 (1.89) 0.483 
      Died 166 (3.31) 351 (6.98) 0.000 
‡p values indicate the differences in treatment success rate while §p indicates differences in unfavourable 
treatment outcomes within categories  using the two sample test of proportions 
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